INTRODUCTION
============

Intralymphatic immunotherapy (ILIT) was introduced recently as a new modality of allergen-specific immunotherapy (AIT); in this approach, only three intralymphatic injections induce marked clinical improvements as early as 4 months after the day of the first injection, and last for 3 years.[@B1][@B2][@B3][@B4][@B5][@B6] Moreover, ILIT causes fewer and milder adverse reactions. However, clinical efficacy has been questioned.[@B7] The efficacy and adverse effects of ILIT for *Dermatophagoides farinae* (Df), *Dermatophagoides pteronyssinus* (Dp), and dog allergens, which are indoor allergens common globally, should be investigated. Furthermore, use of multiple allergens in ILIT warrants further investigation.

In this study, we evaluated the clinical efficacy and adverse effects of ILIT using aqueous Df, Dp, dog and cat allergens or mixtures thereof in patients with allergic rhinitis.

MATERIALS AND METHODS
=====================

Study population
----------------

We enrolled subjects with AR, symptoms of which were provoked by Df, Dp, dog, and/or cat allergens. The subjects met the following enrollment criteria described below. 1) Sensitization proven by skin prick test (SPT) and serum level of allergen-specific IgE measured by ImmunoCAP® (ThermoFisher Scientific, Uppsala, Sweden). Subjects were regarded as being sensitized to an allergen if, according to the SPT, the allergen/histamine (A/H) ratio in the wheal was ≥1 and serum level of allergen-specific IgE was ≥0.35 kU/L. 2) Complaints of AR symptoms during exposure to house dust, dog and/or cat in daily life.

Study design
------------

At the first visit, patient eligibility was determined, information about the study was provided to subjects, written consent was obtained from subjects, and rescue medications including oral antihistamine (cetirizine) and nasal glucocorticosteroid spray (ciclesonide) were prescribed ([Supplementary Fig. 1](#S2){ref-type="supplementary-material"}). The patients were also asked to administer oral antihistamines with or without a nasal glucocorticosteroid spray, according to the recommendation of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines.[@B8]

At the second visit, pretreatment status was evaluated using questionnaires addressing allergic symptoms, and SPT, intradermal test (IDT), and nasal allergen provocation test (NAPT) results. Questionnaires used to assess allergic symptoms included the Sinonasal Outcome Test-20 (SNOT-20),[@B9] and Rhinoconjunctivitis Quality of life Questionnaire (RQLQ).[@B10] SPTs and IDTs were performed using serial dilutions of extracts of the sensitized allergen Df, Dp, dog, and/or cat (HollisterStier, New Orleans, LA, USA) according to the manufacturer\'s instructions. In subjects with Df and/or Dp allergy, NAPTs with the sensitized allergen were performed as previously described.[@B11] In addition to AR symptoms during the NAPT, the mean volume (cm^3^) of the nasal cavity in the anterior nasal segment (volume 2-6 cm) was measured before the NAPT (baseline test) and every 15 minutes during NAPT by acoustic rhinometry (SRE 2000 Rhinometer; Rhinometrics, Lynge, Denmark) according to the guidelines of the Standardization Committee on Acoustic Rhinometry.[@B12] Subjects were asked to stop oral cetirizine (half-life: 8 h) and nasal ciclesonide spray (half-life: 3.5 h) 3 days before the second visit to ensure the validity of the SPT, IDT, and NAPT results.

At visits 3 to 5, the study subjects received three 0.1 mL injections of their sensitized allergen extract at 4-week intervals. Using ultrasound guidance and a 25-gauge needle, aqueous allergen extracts (HollisterStier, New Orleans, USA) were aseptically injected into the superficial inguinal lymph node in the right-side groin.[@B1][@B2][@B3][@B4][@B5][@B6][@B7] Before the injections, aspiration was performed to avoid inadvertent intravascular administration. After each injection, subjects were closely monitored for 1 h with checking of vital signs at 5-min intervals, and adverse events, if any, were recorded. Adverse events due to previous injections were also checked before the next injection at visits 4 and 5. Large local reactions (swelling \> 10 cm in diameter that persisted for \> 24 h) were identified, and systemic hypersensitivity reactions were graded using the Mueller classification.[@B1][@B13] At visit 3, venous puncture was performed to measure the serum levels of total IgE, allergen-specific IgE, and allergen-specific immunoglobulin G4 (IgG4), and subjects were asked to rate the pain provoked by intralymphatic injection and that by venous puncture using the visual analog scale (VAS) ranging from 0 to 100 mm.[@B1][@B3] The initial dose of allergen was a 1,000-fold dilution of the maximal concentration of allergen extract for subcutaneous immunotherapy (SCIT) (initial concentration: 30 AU/mL for Df or Dp; 10 AU/mL for cat hair; and 1:1/10 weight/volume (w/v) for dog hair/dander; HollisterStier) in a volume of 0.1 mL. After the first injection, the allergen concentration was escalated 3-fold on the day of the second injection, and 10-fold on the day of the third injection, if there was no or mild local or systemic hypersensitivity reaction. The allergen concentration did not change on the day of second or third injection if there was a moderate local or systemic reaction. The allergen concentration was decreased by 3- to 1,000-fold from the previous concentration if there was a severe local or systemic reaction. When 2 or more allergens were injected into the inguinal lymph node, the allergen mixture was produced in a volume of 0.1 mL to preserve the target concentration of each allergen.

At visits 6 and 7, posttreatment status was evaluated in a manner similar to that at the first visit and blood sampling was performed, respectively. Adverse events after the third injections were also checked at visit 6.

The study was approved by our Institutional Review Board and monitored by our Human Research Protection Committee. This study was registered in an open-access trials registry (ClinicalTrials.gov identifier: NCT02301884).

Statistical analysis
--------------------

Statistical analysis was performed using PASW 20.0 (SPSS Inc. Chicago, IL, USA). Continuous variables were analyzed by paired Man-Whitney U test, whereas categorical variables were analyzed by Fisher\'s exact test. A *P* value \<0.05 was deemed to indicate statistical significance.

RESULTS
=======

Informed consent was obtained from a total of 24 subjects; however, 4 did not attend a further visit ([Supplementary Fig. 2](#S3){ref-type="supplementary-material"}). Therefore, pre-ILIT evaluation of 20 subjects was carried out, but 5 dropped out due to lack of time to participate in this study, and 2 due to occurrence of anaphylaxis during SPT and IDT with Df and Dp allergens, And 2 due to lack of time after the first injection of ILIT. The post-ILIT evaluation was thus performed in 11 subjects. The demographic characteristics of the subjects are shown in [Table 1](#T1){ref-type="table"}.

Local and systemic adverse effects during ILIT
----------------------------------------------

The pain of intralymphatic injection was comparable to that of venous puncture ([Supplementary Fig. 3](#S4){ref-type="supplementary-material"}). Seven subjects complained of mild local or systemic reaction (grade 0-1 in the Mueller classification); however, four experienced large local reactions or moderate-to-severe systemic reactions of grade 2-3 in the Mueller classification ([Table 2](#T2){ref-type="table"}). Despite those severe reactions, they strongly desired to undergo further ILIT as scheduled, so that additional injections were performed using 3-, 100-, or 1,000-fold dilutions of the concentration previously applied.

AR symptoms, quality of life, and prescription of rescue medication
-------------------------------------------------------------------

The SNOT-20 and RQLQ scores were significantly decreased 4 months (*P*=0.012 and *P*=0.007, respectively) and 1 year (*P*=0.047 and *P*=0.009, respectively) after ILIT compared with the baseline levels ([Figure](#F1){ref-type="fig"}).

In general, rescue medications, with the exception of antihistamine eye drops, were prescribed less frequently after ILIT. The frequency of nasal corticosteroid spray prescription was significantly reduced 4 months after the first injection of ILIT (*P*=0.04; data not shown).

Nasal reactivity to house dust mites in NAPTs
---------------------------------------------

Nasal symptoms during nasal challenge with house dust mite allergens in NAPTs were significantly reduced 1 year after ILIT (*P*\<0.05; [Supplementary Fig. 4](#S5){ref-type="supplementary-material"}). The decrease in nasal cavity volume during NAPTs was also alleviated 1 year after ILIT; however, the magnitude of the decrease was not significant.

Skin reactivity to allergens in the SPT and IDT
-----------------------------------------------

Skin reactivity to allergens in the SPT and IDT was generally increased after ILIT, albeit without statistical significance. Skin reactivity to Dp in the SPT was significantly increased 1 year after ILIT (*P*\<0.05; data not shown).

Serum total IgE and serum allergen-specific IgE and IgG~4~
----------------------------------------------------------

Serum levels of allergen-specific IgE to Df and Dp were significantly increased 4 months after ILIT (*P*\<0.05), but they decreased 1 year after ILIT (*P*\<0.05; [Supplementary Fig. 5](#S6){ref-type="supplementary-material"}). The serum level of allergen-specific IgG4 to Df showed a similar trend; however, it was not significantly different 4 months and 1 year after ILIT compared with baseline. The serum level of allergen specific IgG4 to Dp was significantly increased 1 year after ILIT compared with baseline (*P*\<0.05). Neither the serum level of allergen-specific IgE and IgG4 to dog and cat nor the serum total IgE level changed significantly after ILIT (data not shown).

DISCUSSION
==========

All previous studies of ILIT have reported that ILIT causes only mild adverse effects.[@B1][@B2][@B3][@B4][@B5][@B6][@B7] However, we observed that ILIT could cause severe adverse reactions even at very low concentrations that were not expected to cause serious reactions in SCIT. We therefore propose that AIT of the lymph nodes is not entirely safe, as they are connected to the systemic circulation through the thoracic duct, and ILIT can cause severe adverse reactions even when very low doses of allergen are used.

In subjects who showed moderate-to-severe systemic reactions (subjects 5, 6, and 11), ILIT using Df and Dp at concentrations that, according to SPTs, led to A/H ratios in wheals of more than 1 caused systemic reactions ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). We thus suggest that the allergen concentration be reduced in hypersensitized patients, as recommended by the manufacturer of SCIT. In detail, we propose that SPTs be performed with serial dilutions of allergens, that the initial dose of allergen in ILIT not exceed the maximal concentration leading to an A/H ratio in wheals of less than 1, and that we carefully monitor patients undergoing ILIT with allergens at doses exceeding this concentration.

No severe reaction occurred in 2 patients (subject numbers 1 and 7 in [Supplementary Table 1](#S1){ref-type="supplementary-material"}), although the allergen dose used in ILIT exceeded the above-mentioned concentration. Regarding severe local and systemic reactions to ILIT, we must also consider other factors such as the type and preparation of allergen and patient clinical characteristics other than hypersensitization.

Like most previous studies of ILIT, the symptoms of AR and quality of life in this study were improved as early as 4 months after the first injection of ILIT, and lasted for 1 year.[@B1][@B2][@B3][@B4][@B5][@B6] In NAPTs, nasal reactivity to HDM allergens was decreased after ILIT as previously described.[@B1][@B2][@B3][@B5][@B6] Furthermore, the serum levels of allergen-specific IgE and IgG~4~ to Df and Dp were increased 4 months after ILIT, being consistent with the results of previous studies.[@B2][@B3][@B14] However, these levels were again decreased 1 year after ILIT. Previous studies have reported decreased allergen-specific IgE levels 3 years after ILIT[@B1] and decreased allergen-specific IgG~4~ levels 1 year after ILIT.[@B14] Regarding dog and cat allergens, we failed to observe any significant change in the level of allergen-specific IgE or IgG~4~, due to an inadequate number of subjects. Unlike previous reports,[@B1][@B2][@B6][@B7] skin reactivity to allergens in SPT and IDT generally increased after ILIT in this study.

This study has several limitations. First, it is not placebo-controlled. Therefore, the effects of other factors---including pharmacotherapy, allergen avoidance or other lifestyle modifications, natural course, and subject expectations---should be considered. Additionally, application of ILIT using multiple allergens might have hampered interpretation of the results of this study.

Despite these limitations, our study provides useful information on ILIT. First, the findings suggest that ILIT can provoke serious local or systemic reactions and that a reduced allergen dose, especially of aqueous allergen extracts, should be applied in hypersensitized patients. Secondly, this study is the first of ILIT to evaluate Df, Dp, and dog allergens, which are prevalent globally. Thirdly, this is to our knowledge the first study to use multiple allergens in ILIT.

In conclusion, ILIT can rapidly improve AR symptoms and reduce the frequency of prescription of rescue medication, and this effect lasts for 1 year. However, in hypersensitized patient, ILIT can also cause severe systemic and/or local hypersensitivity reactions when performed using aqueous allergen extract.
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SUPPLEMENTARY MATERIALS
=======================

###### Supplementary Table 1

Allergen/histamine wheal ratio in baseline SPT

###### Supplementary Fig. 1

Study outline. At visit 1, rescue medications were prescribed and diary cards were issued after informed consent was obtained; at visit 2, pre-ILIT status was evaluated; at visits 3 to 5, subjects received intralymphatic immunotherapeutic allergen injections; and at visits 6 to 7, post-ILIT status was evaluated.

ILIT, intralymphatic immunotherapy; SNOT-20, Sinonasal Outcome Test-20; RQLQ, Rhinoconjunctivitis Quality of Life Questionnaire.

###### Supplementary Fig. 2

Participant flowchart. Informed consent was obtained from 24 subjects, of whom 11 and 2 dropped out due to lack of time and an anaphylactic reaction during SPT and IDT, respectively. Thus, the post-ILIT evaluation was performed on a total of 11 subjects.

ILIT, intralymphatic immunotherapy; SPT, skin prick test; IDT, intradermal test.

###### Supplementary Fig. 3

Pain of intralymphatic immunotherapy. Subjects were asked to compare the pain of intralymphatic injection with that of venous puncture using the visual analogue scale ranging from 0 to 100 mm (n=11).

VAS, visual analog scale; N.S., not significant.

###### Supplementary Fig. 4

Nasal reactivity to Df and/or Dp as determined by the nasal allergen provocation test.

Df, Dermatophagoides farinae; Dp, Dermatophagoides pteronyssinus; Total VAS, the sum of the 5 VAS scores (total score 0-500); Vol. in 2-6 cm, volume in 2-6 cm by acoustic rhinometry; %basal, percent to baseline level before challenge during the NAPT.

^\*^*P*\<0.05 compared with baseline.

###### Supplementary Fig. 5

Serum levels of allergen-specific IgE and IgG4 to Df and Dp. (A) Serum Df-specific IgE; (B) Serum Df-specific IgG4; (C) Serum Dp-specific IgE; (D) Serum Dp-specific IgG4.

IgE, immunoglobulin E; IgG4, immunoglobulin G4; Df, *Dermatophagoides farinae*; Dp, *Dermatophagoides pteronyssinus*.

^\*^*P*\<0.05 compared with baseline.

![Subject-reported rhinitis symptoms and quality of life. (A) Sinonasal Outcome Test-20 (SNOT-20) scores. (B) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores.](aair-9-272-g001){#F1}

###### 

Demographic characteristics

![](aair-9-272-i001)

  Subject No.   Gender   Age (year)   Duration of AR (year)   Comorbidities                                Past medical history                   Current treatment       Allergen
  ------------- -------- ------------ ----------------------- -------------------------------------------- -------------------------------------- ----------------------- ------------------
  1             Female   47           3                       None                                         None                                   AH, LA, ICS/LABA        Dog
  2             Female   35           7.5                     Asthma, food allergy, aspirin idiosyncrasy   Otitis media                           AH, ICS                 Df, Dp, dog, cat
  3             Male     42           2                       Asthma                                       None                                   AH, LA, ICS/LABA        Df, Dp, dog, cat
  4             Male     33           5                       None                                         None                                   AH, NCS, LA             Df
  5             Female   22           20                      None                                         Sinusitis, food allergy                AH, NCS                 Df, Dp
  6             Female   50           2                       Asthma                                       Otitis media                           AH, NCS, ICS/LABA       Df, Dp
  7             Female   32           18                      Asthma, sinusitis                            Nasal polyp, urticaria, food allergy   AH, NCS, LA, ICS/LABA   Df, Dp, cat
  8             Male     57           3                       None                                         None                                   AH, NCS, LA             Dp
  9             Female   49           2                       Asthma, hypertension                         None                                   AH, NCS, ED, ICS/LABA   Df, Dp
  10            Male     45           35                      Asthma                                       Otitis media, food allergy             AH, NCS, ED, ICS/LABA   Df, Dp
  11            Female   46           2                       Urticaria, food allergy                      Atopic dermatitis                      AH, NCS, ED             Df, Dp, dog

AR, allergic rhinitis; AH, antihistamine; LA, leukotriene antagonist; ICS, inhaled corticosteroid; LABA, long-acting beta2 agonist; NCS, nasal corticosteroid; ED, antihistamine eye drops; Df, *Dermatophagoides farinae*; Dp, *Dermatophagoides pteronyssinus*.

###### 

Treatment schedule and local/systemic reactions

![](aair-9-272-i002)

^\*^The initial dose of allergen was a 1,000-fold dilution of the maximal concentration of allergen extract for subcutaneous immunotherapy (initial concentration: 30 AU/mL for Df or Dp; 10 AU/mL for cat hair; and 1:1/10 weight/volume (w/v) for dog hair/dander, HollisterStier, New Orleans, USA) in a volume of 0.1 mL. After the first injection, the allergen concentration was escalated 3-fold on the day of the second injection, and 10-fold on the day of the third injection, if there was no or mild local or systemic hypersensitivity reaction. The allergen concentration did not change on the day of second or third injection if there was a moderate local or systemic reaction. The allergen concentration was decreased by 3- to 1,000-fold from the previous concentration if there was a severe local or systemic reaction. ^†^Systemic hypersensitivity reactions were graded using the Mueller classification. ILIT, intralymphatic immunotherapy; AU/mL, allergy units/mL (for Df, Dp, and cat allergens); w/v, weight/volume (for dog allergen); Df, *Dermatophagoides farinae*; Dp, *Dermatophagoides pteronyssinus*; RLQ, right lower quadrant of the abdomen.
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